Postdiagnosis Body Mass Index, Weight Change, & Mortality From PCa, Cardiovascular Disease, & All Causes Among Survivors of NonmetastaticPCa

[cujoe]

As all men on ADT struggle with the side-effect of unwanted weight-gain, this paper reinforces the need to take appropriate measures to minimize/prevent such gains. Coupled with the previous post on Dietary Patterns & PCa Risk (healthunlocked.com/fight-pr..., this research further substantiates that diet and lifestyle play significant roles in PCa outcomes. Also linked is a short MedPage Today interview with two of the paper's authors.

From the Abstract:

* * *

PURPOSE

To investigate the association of postdiagnosis body mass index (BMI) and weight change with prostate cancer–specific mortality (PCSM), cardiovascular disease–related mortality (CVDM), and all-cause mortality among survivors of nonmetastatic prostate cancer.

METHODS

Men in the Cancer Prevention Study II Nutrition Cohort diagnosed with nonmetastatic prostate cancer between 1992 and 2013 were followed for mortality through December 2016. Current weight was self-reported on follow-up questionnaires approximately every 2 years. Postdiagnosis BMI was obtained from the first survey completed 1 to < 6 years after diagnosis. Weight change was the difference in weight between the first and second postdiagnosis surveys. Deaths occurring within 4 years of the follow-up were excluded to reduce bias from reverse causation. Analyses of BMI and weight change included 8,330 and 6,942 participants, respectively.

RESULTS

Postdiagnosis BMI analyses included 3,855 deaths from all causes (PCSM, n = 500; CVDM, n = 1,155). Using Cox proportional hazards models, hazard ratios (HRs) associated with postdiagnosis obesity (BMI ≥ 30 kg/m2) compared with healthy weight (BMI 18.5 to < 25.0 kg/m2) were 1.28 for PCSM (95% CI, 0.96 to 1.67), 1.24 for CVDM (95% CI, 1.03 to 1.49), and 1.23 for all-cause mortality (95% CI, 1.11 to 1.35). Weight gain analyses included 2,973 deaths (PCSM, n = 375; CVDM, n = 881). Postdiagnosis weight gain (> 5% of body weight), compared with stable weight (± < 3%), was associated with a higher risk of PCSM (HR, 1.65; 95% CI, 1.21 to 2.25) and all-cause mortality (HR, 1.27; 95% CI, 1.12 to 1.45) but not CVDM.

CONCLUSION

Results suggest that among survivors of nonmetastatic prostate cancer with largely localized disease, postdiagnosis obesity is associated with higher CVDM and all-cause mortality, and possibly higher PCSM, and that postdiagnosis weight gain may be associated with a higher mortality as a result of all causes and prostate cancer.

* * *

Link to ASCO's Journal of Clinical Oncology's Abstract:

ascopubs.org/doi/abs/10.120...

Full research report via sci-hub is here:

scihub.to/10.1200/JCO.19.02185

MedPage Today interview with authors is here:

medpagetoday.com/reading-ro...?

Live Well to Be/Stay Well - K9

[NPfisherman]

Eat right, exercise, proper nutrition. The problem is that drugs like abiraterone combined with prednisone (the real problem) make it hard to lose weight and keep it off. Steroids and weight gain go hand in hand. The new water soluble formulation of abiraterone while getting 40% higher bioavailability will be used at a lower dose. I do not know if the dose for prednisone will be decreased consequently making it easier to maintain a stable weight...

Don Pescado

[cujoe in reply to NPfisherman]

Good info from the man with his hand on the Science pulse.

Stay Well - K9